Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer - Summary - MDSpire

Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

  • By

  • Ryan D. Chow

  • John Rothen

  • Jessica B. Long

  • Pamela R. Soulos

  • Xiao Wang

  • Ronac Mamtani

  • Shuangge Ma

  • Natalia Kunst

  • Michaela A. Dinan

  • Cary P. Gross

  • May 27, 2026

  • 0 min

Share

Objective:

To identify payer- and region-level factors associated with access to guideline-concordant genomic testing in modern oncology care.

Key Findings:
  • BGP use has increased over time but remains underused.
  • MA plans are associated with delayed treatment initiation and reduced survival among patients with metastatic lung cancer.
  • Geographic variation significantly influences cancer treatment decisions and BGP use.
Interpretation:

Limitations:
  • Study did not stratify patients by specific histopathologic cancer types due to data limitations.
  • Exclusion of patients with mixed FFS and MA coverage may limit generalizability.
Conclusion:

Original Source(s)

Medicare Insurance Type and Broad Genomic Profiling in Metastatic Cancer

  • by Ryan D. Chow, John Rothen, Jessica B. Long, Pamela R. Soulos, Xiao Wang, Ronac Mamtani, Shuangge Ma, Natalia Kunst, Michaela A. Dinan, Cary P. Gross

  • May 27, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study